Abbott $385M Baby Formula Contamination Settlement
Analysis based on 7 articles · First reported Sep 14, 2026 · Last updated Sep 15, 2026
The settlement removes a major legal overhang for Abbott Laboratories at a modest cost relative to its balance sheet, likely limiting negative pressure on the stock while keeping reputational and regulatory scrutiny on its nutrition division. Broader food-safety and infant-formula manufacturers may face heightened compliance expectations and potential liability exposure, a mild negative for the sector.
Abbott Laboratories agreed to pay approximately $385 million to resolve federal and state civil allegations that it sold contaminated powdered infant formula to government nutrition programs between January 2018 and December 2022. The United States — United States Department of Justice announced the settlement, under which Abbott will pay $348.7 million to the federal government and $36.3 million to state Medicaid and WIC programs. The government alleged that Abbott manufactured formula at facilities in Sturgis, United States — Michigan, and Casa Grande, United States — Arizona, under conditions that failed statutory, regulatory, and contractual requirements, including recurring roof leaks, damaged spray dryers, skipped bacterial testing, and withheld contamination records. The Sturgis plant, the largest infant formula facility in the country, was shut down in February 2022 after four infants fell ill with Cronobacter sakazakii, reportedly contributing to two deaths, and the closure worsened a nationwide formula shortage. Three former Abbott employees, Austin Scott, Kristine Cooper, and Loren Cooper, filed a qui tam False Claims Act lawsuit in 2022 and will collectively receive $69 million from the federal recovery. The settlement includes no admission or finding of fault or liability, and Abbott said no unopened distributed formula ever tested positive for Cronobacter sakazakii. The government closed its criminal investigation into the matter. In August, Abbott separately agreed to pay $670 million to settle lawsuits alleging it hid the risk that its premature-infant formula could cause a deadly bowel disease.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard